---
schema_version: "secwatch.filing_event.v1"
accession: "0001703057-23-000020"
form_type: "8-K"
ticker: "ABCL"
cik: "0001703057"
company_name: "AbCellera Biologics Inc."
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T08:43:30.618099+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AbCellera Q2 revenue drops 78% to $10M; net loss widens to $0.11/share

## Summary
- Total revenue $10.1M vs $45.9M in Q2 2022; research fees fell to $9.8M from $12.5M.
- Net loss $30.5M ($0.11/sh) vs net loss $6.8M ($0.02/sh) in Q2 2022; R&D spending rose to $36.5M.
- Cash, equivalents and marketable securities $822.9M; secured $220M in strategic financing from Canadian govts.
- Cumulative partnered program starts up 20% YoY to 106; 9 molecules advanced to clinic vs 6 a year ago.
- Total programs under contract 177 with 41 partners, up from 164 and 38 a year ago.

## SEC filing metadata
- accession: 0001703057-23-000020
- form_type: 8-K
- ticker: ABCL
- cik: 0001703057
- company_name: AbCellera Biologics Inc.
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703057/000170305723000020/0001703057-23-000020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703057/000170305723000020/abcl-20230803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001703057-23-000020
- JSON: https://secwatch.observer/filing/0001703057-23-000020.json
- Plain text: https://secwatch.observer/filing/0001703057-23-000020.txt

## Key facts
- Earnings Releases
  AbCellera Biologics Inc. reported the second quarter of 2023 results: revenue $10.1 million, net income $30.5 million, EPS $(0.11) per share on a basic and diluted basis.
  - Period: the second quarter of 2023
  - Revenue: $10.1 million
  - Net income: $30.5 million
  - EPS: $(0.11) per share on a basic and diluted basis
  - Result: reported results
  source text: this funding will drive value in multiple dimensions of our business, including advancing more pre-partnered programs to the clinic.” Q2 2023 Business Summary ● Earned $10.1 million in total revenue. ● Generated a net loss of $30.5 million, compared to a net loss of $6.8 million in Q2 2022. ● Maintained a cumulative total of 177 programs under contract with
  evidence_url: https://www.sec.gov/Archives/edgar/data/1703057/000170305723000020/0001703057-23-000020-index.htm
- Earnings Releases
  AbCellera Biologics Inc. reported financial results for quarter ended June 30, 2023.
  - Period: quarter ended June 30, 2023
  - Result: reported results
  source text: On August 3, 2023, AbCellera Biologics Inc., (the “Company”), issued a press release announcing its financial and operational results for the quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1703057/000170305723000020/0001703057-23-000020-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.